| INTRODUCTION
Genetic etiologies account for 4 to 41% of patients with intellectual disability (ID) or developmental delay (DD), depending on the recruitment strategy, type and resolution of clinical exam and laboratory techniques applied (Battaglia, Bianchini, & Carey, 1999; Bernardini et al., 2010; Moeschler, 2008; Moeschler & Shevell, 2014) . Concluding a specific genetic diagnosis often has a major impact on the management plan for a child with ID/DD and counselling of families regarding recurrence risk. Not only can this guide patient management and efficient care but also it will make possible the implementation of preventive measures such as pre-conceptual counselling and prenatal testing.
In Sub-Saharan Africa, such as in other developing countries, the prevalence of ID is thought to be higher than in developed countries, mainly attributed to environmental factors including infection and suboptimal healthcare systems (Durkin, 2002; Emerson, 2007; Kleinman & Eisenberg, 1995; Roeleveld, Zielhuis, & Gabreels, 1997) . The currently implemented public healthcare systems can result in a lack of neonatal screening programs, partial or complete absence of pediatric assessment of normal developmental milestones during wellchild visits and lack of psychometric evaluation for children with delayed development. This leads to the lack of accurate figures on the prevalence of ID in Sub-Saharan Africa and the distribution by causes in this setting. In particular, data on the genetic etiology of ID in Central Africa are scarce. With the exception of some case reports, few studies have investigated a cohort of patients with ID using advanced technologies (Uwineza et al., 2014 (Uwineza et al., , 2016 . Therefore, DD/ID is still mainly attributed to "mystical" causes in this part of the world (Abasiubong, Obembe, & Ekpo, 2008) . A study of genetic causes will provide evidence regarding the biological bases of ID, potentially providing scientific evidence to campaign against false beliefs and help to improve information for management and therapeutic actions directed by caregivers.
Reaching a genetic etiologic diagnosis in an individual with ID is based on different but complementary approaches. Clinical evaluation generating a potential differential diagnosis is at the forefront of this process. This relies on knowledge generated from clinical presentation in previously described patients. Unfortunately, this resource is often not available for African patients. Moreover, clinical presentation shows some ethnic differences (McDonald-McGinn et al., 2005; Moore et al., 2007; Ofodile, Bokhari, & Ellis, 1993; Schwartz et al., 1988; Talbert, Kau, Christou, Vlachos, & Souccar, 2014) , making it difficult to clinically recognize an African patient presenting with a syndrome that is rather well described in other world populations. Efforts are being made to supplement the scientific community with clinical descriptions of patients from diverse ethnicities (Kruszka, Addissie, et al., 2017a; Kruszka, Porras, Addissie, et al., 2017b; Kruszka, Porras, Sobering, et al., 2017c ) and our study is part of these efforts.
Besides the clinical evaluation, various genetic tests are often performed to further narrow the clinically generated differential diagnosis. These tests are prioritized based on the most frequent known genetic abnormalities and genes/variants for the reported phenotype.
Chromosomal aberrations, including aneuploidies and submicroscopic aberrations, represent the major diagnostic category in previous studies (Boone et al., 2010; Breman et al., 2012; Cheung et al., 2005; Devriendt, Holvoet, & Fryns, 2003; Gambin, Yuan, et al., 2017b; Lee et al., 2013; Lu et al., 2007; Morrow, 2010; Rauch et al., 2006; Shao et al., 2008; Wiszniewska et al., 2014) . Frequent submicroscopic aberrations are recurrent nonallelic homologous recombination (NAHR)-mediated copy-number variants (CNVs) (Dittwald, Gambin, GonzagaJauregui, et al., 2013a; Dittwald, Gambin, Szafranski, et al., 2013b) .
Depending on the resolution of the applied platform, submicroscopic imbalances represent 6 to 20% of causes (Chong et al., 2014; Lupski, 2015; Mannik et al., 2015; Nicholl et al., 2014; Rauch et al., 2006; Utine et al., 2014) . The most common monogenic cause of ID is the Fragile-X syndrome, which results from mutations in the FMR1 gene (MIM 309550). For this reason, all patients with ID, especially males, are often investigated for the CGG repeat (Moeschler & Shevell, 2014) . Mutations in X-linked genes are a common cause of ID and explain an excess of males with ID (Mandel & Chelly, 2004; Ropers, 2010) . X-linked ID is observed in 6-12% of males with ID (Hu et al., 2016; Tzschach et al., 2015) . However, XLID is heterogeneous with more than 100 genes identified to date. Thus, Next Generation Sequencing (NGS) offers a more efficient and cost-effective opportunity to screen for X-linked ID (Gambin, Akdemir, et al., 2017a; Tzschach et al., 2015) . X-linked inheritance is suspected when a clinically recognizable X-linked syndrome is observed or when ID segregates in the pedigree in a clear X-linked Mendelian pattern. In the absence of an established X-linked recessive pattern in pedigrees of families, skewed X-inactivation in the mother of a boy with unexplained ID is an indication of possible XL-ID. Likewise, skewed Xinactivation in a girl with unexplained ID may also indicate that an underlying X-linked mutation explained her ID (Brady et al., 2015; Fieremans et al., 2016) . In this study, we selected cases with a high probability of X-linked ID for NGS testing.
The overall aim of this study is to use a comprehensive approach to provide an estimate for genetic etiologic causes of ID/DD and insights into the clinical presentation of some genetic conditions in a Central African country.
| MATERIALS AND METHODS

| Ascertainment of patients and ethical considerations
Patients were recruited from four specialized schools and tertiary hospitals in Kinshasa, capital of DR Congo. Informed consent was administered in accordance with human subject studies as delineated by the Declaration of Helnsinki. Procedures, risks, and benefits of the study, as well as the patient's right to withdraw were explained to parents, then we received signed written consents for 127 patients with developmental delay/ID. We applied an anonymous and de-identified coding system to protect participants' privacy. Our research protocol was approved by the ethical committee of the Public Health School of the Kinshasa, (registry number ESP/CE/008/2015). Patients were evaluated in the field by a medical expert, then clinical data and photographs were reviewed by a medical geneticist in the Centre for Human Genetics in the University hospitals of Leuven, Belgium. Body measurements were converted into standard deviation scores using the Centers for Disease Control (CDC, Atlanta, GA) growth charts. Clinical description was made according to the standard terminology described in the elements of morphology series (Allanson, Biesecker, Carey, & Hennekam, 2009 ). Patients were classified as syndromic when they had at least three minor dysmorphic features, regardless of major malformations. The Informed Consent process is further described in Supporting Information.
| Genetic analyses
A variety of genetic laboratory analytical tools were applied in a stepwise manner as described in Figure 
| DNA extraction
Venous blood was obtained from a peripheral vein and genomic DNA was extracted by the salt saturation method as previously described (Miller, Dykes, & Polesky, 1988) . The first 45 samples were extracted at the Centre for Human Genetics of the KU Leuven (Belgium) whereas the latter ones were extracted at the Institut National de Recherche Biomédicale (INRB) in Kinshasa (DR Congo).
| Fragment analysis for ARX CAG repeat
We used two primer sets (Primer 4044 ARX-2F and JR2-FAM) to amplify the first two CAG stretches in the ARX (Allen, Zoghbi, Moseley, Rosenblatt, & Belmont, 1992 
| FMR1 testing
To evaluate the size of the CGG repeat fragment, the target region was amplified during a PCR reaction using the PCR-enhancer kit 
| Array-CGH
All patients without recognizable syndrome and those with unconfirmed clinical diagnostic were initially selected for aCGH. We performed whole genome copy number screening using stripped CytoSure™ ISCA v2 array 8 × 60k format (OGT, Oxford, UK). We 
| qPCR
To confirm results from array-CGH performed with strip slides, to evaluate parental inheritance or to confirm a clinical diagnosis of Down syndrome, we performed qPCR on LightCycler480 ® (Roche).
The Primer3web version 4.0.0 tool (http://bioinfo.ut.ee/primer3/) was used to design primers (primer listed in Supporting Information, Table S1 ). We used the ddCt relative quantification method 
| X-chromosome inactivation pattern
Genomic DNA was subjected to the standard androgen receptor (AR, MIM# 313700) assay to determine X-inactivation ratios as previously described (Allen et al., 1992) .
| Whole exome sequencing
Girls with highly skewed XCI and boys whose mothers showed highly skewed XCI were eligible for WES. Since one girl with skewed XCI carries a pathogenic copy deletion, WES was performed for one girl and two boys. The experiment was performed in the Genomics Core Facility (KU Leuven, Belgium) for patients DRC-0042 and DRC-0032, using the SeqCap EZ Human Exome Library v3.0 (Roche, NimbleGen) and the Illumina HiSeq2000 platform, and at the Baylor College of Medicine (Houston, TX) for patient DRC-0108, using HiSeq instrument following the procedure previously reported (Bainbridge et al., 2011; Challis et al., 2012; Lupski et al., 2013; Reid et al., 2014) . For this last sample, a sequencing yield of 6.1 Gb was generated with 92%
of the targeted exome bases covered to a depth of 20× or greater. Initial bioinformatics was performed at the Baylor Hopkins Center for
Mendelian Genomics following the algorithm described previously (Reid et al., 2014) . Once all data were returned to the Genomics Core, they went through the inhouse bioinformatic pipeline previously described (Fieremans et al., 2016) with the difference that annotated vcf files were converted into Excel books to allow sequential hypothesis driven data filtering. Additionally, we also reran the data analysis on Moon ® , a commercial Artificial Intelligence based platform developed by Diploid (www.moon.dipoid.com). Moon uses artificial intelligence to autonomously diagnose rare Mendelian diseases within a record time. This algorithm suggests a causal variant based on patient input data and extensive knowledge of rare disease genetics.
Variants were classified according to the ACMG recommendations (Richards et al., 2015) .
| Sanger sequencing
Sequencing primers used for Sanger validation are listed in Supporting Information (Table S2) 
| Clinically recognized syndromes
In 19 patients, the clinical diagnosis of Down syndrome was made ( Figure 2 and Table 2 ). In addition to these subjects, we clinically diag- (Laperuta et al., 2007; Poirier et al., 2006; Stepp et al., 2005) . 
| Fragile-X syndrome
| Microarray-CGH
Chromosomal microarray-CGH was initiated for the same group that received FMR1 testing. In 19 cases, the DNA samples did not pass the quality criteria for array-CGH and were thus excluded. Hence the results presented below are from 86 patients. CNVs were classified following the ACMG classification guidelines (Kearney et al., 2011) .
Ten CNV's were considered to be likely pathogenic or pathogenic for ID in 10 out of 86 tested patients (11.6%). All identified CNVs were confirmed using an independent technique, qPCR (in 9/10) or SNParray (in 1/10 patient with a mosaic deletion) ( Table 1) . Facial photographs of patients with relevant CNVs are presented in Figure 3 whereas detailed clinical description can be found in Table 2 .
FIGURE 2 Clinical photographs of patients with Down syndrome. Legend: Detailed clinical description of patients with Down syndrome are presented in Table 1 [Color figure can be viewed at wileyonlinelibrary.com] (Figure 3j ).
NA: Not Available.
| X-chromosome inactivation analysis
From our cohort of individuals with ID, we investigated the X chromosome inactivation (XCI) profile in all 27 unrelated females index patients, as well as 41 mothers of male patients from whom DNA was available. In total, 6 highly skewed profiles were identified. Of 41 mothers of boys with ID tested, 3 (7.32%, CI: 1.89-18.63) had a highly skewed XCI (i.e., ≥90%). In addition, 3 other mothers (7.32%) had moderate skewed XCI (i.e., 80%≤XCI < 90%), 8 (19.51%) had mild skewed XCI (70%≤XCI < 80%), whereas 27 (65.85%) showed random X-inactivation (i.e., <70). Among the 27 female indexes with ID, we detected 3 (11.11%) with a highly skewed X-inactivation. Five (18.52%) had moderate and mild skewing, respectively; and 14 (51.85%) had random X-inactivation.
| Whole exome sequencing
The WES was performed in the boy with suspicion of Noonan syndrome (DRC-0098) and three patients from XCI study, including two boys (DRC-0018 and DRC-0042) and one girl (DRC-0032). One of the girls with highly skewed XCI profile (DRC-0018) had a pathogenic CNV, thus was not considered for WES. DNA from the two other patients with history of highly skewed XCI did not pass the quality criteria for WES.
In patient DRC-0018, novel missense variant, potential candidate, was identified in the X-linked gene TAF1. This patient is considered for publication in a large cohort of patients with TAF1 mutations and is thus not further discussed here.
In Patient DRC-0042, we did not identify any plausible X-linked variant. However, we identified two variants in the AMINOACYLASE 1 gene (ACY1, MIM 104620) of this patient. One of these variants was inherited from the mother and the father was not available for testing consistent with the subject having biallelic variants for an AR disease trait. The maternally inherited variant (ACY1: NM_000666:
exon15:c.C1156T;p.R386C; rs2229152) was previously reported in the homozygous state in 1 patient and classified as pathogenic after functional analysis revealed reduced enzymatic activity (Sommer et al., 2011) . However, this variant is present in the homozygous state in 3 individuals of African origin listed in gnomAD where the phenotype is not specified nor whether this sample was sequenced in a cohort with ID or neurocognitive phenotypes such as ASD or schizophrenia.
The previous patient presented with several episodes of febrile seizures, severe mental retardation, autistic features and lack of speech development and brain cortical dysplasia with grey matter heterotopia.
This clinical presentation is far more severe than the manifestations observed in our patient (non-syndromic ID and autistic-like behavior).
Given the rather limited clinical overlap and the presence of this variant in the homozygous state in unaffected individuals, and despite the functional study, this variant remains a variant of unknown clinical significance (VUS) according to the ACMG guidelines (Richards et al., 2015) .
The second ACY1 variant is a rare missense variant (ACY1: With 19 cases out of 127 (14.8%; CI: 9.531%-21.97%), Down syndrome is the most prevalent genetic cause in our cohort. This prevalence of Down syndrome is also observed in most series investigating ID (Devriendt et al., 2003; Rauch et al., 2006) . However, our frequency is seemingly higher than 9.2% reported by Rauch et al. in Switzerland, and 7 .1% reported by Devriendt et al in Flanders. This could be due to the absence of prenatal screening programs in DR Congo and to the larger size of families potentially resulting in more mothers with advanced maternal age, thus exposing the last pregnancy to higher risk for Down syndrome. More than 75% of mothers of children with Down syndrome were aged ≥35 years, which is consistent with the contention of advanced maternal age contributing to our observations as this is a well-known risk factor for nondisjunction trisomy 21 (Csermely, Czeizel, & Veszpremi, 2015; Snijders, Sebire, Faria, Patel, & Nicolaides, 1995) .
The index with Partington syndrome (MIM 309510) as well as his similarly affected brother had the typical clinical presentation as described in Caucasian patients in the literature (Cossee et al., 2011; Gedeon, Partington, & Mulley, 1994; Partington et al., 1988 (Rauch et al., 2006) .
A broad genetic screening was performed for the remaining patients. We prioritized FMR1 testing and microarray-CGH in the current study to be consistent with the guidelines for genetic screening tests in unexplained ID (Miller et al., 2010; Moeschler & Shevell, 2014 The proportion of mothers with highly skewed XCI is not significantly different from the normal population of adult females where highly skewed X-inactivation was observed in 3.6% (22 out of 415 females) (Amos-Landgraf et al., 2006) . However, when considered amongst the 68 female patients and mothers of affected boys, our prevalence (13.6% is statistically higher compared to 9.8% general proportion reported by Amos-Landgraf (Amos-Landgraf et al., 2006) .
Both the small size of the population and the selective character of the sample may explain the apparent enrichment of skewed XCI in this cohort.
One boy was compound heterozygous for two variants in the ACY1. Mutations in ACY1 are responsible for Aminoacylase 1 deficiency, an autosomal recessive metabolic disease characterized by ID, seizures, hypotonia, motor delay and, in one family, sensorineural hearing loss (Ferri et al., 2014; Van Coster et al., 2005) . Interestingly, one of the two mutations (p.R386C) was previously reported as pathogenic and proven to down-regulate the activity of the Aminoacylase-1 (Sommer et al., 2011) . Confirmation of this disorder can be done by metabolic testing on urine. However, this is not available locally for the moment. In the other boy, a likely causal mutation was identified in TAF1, a gene recently identified as candidate gene for XL-ID (Hu et al., 2016; O'Rawe et al., 2015) . However, more clinical evidence and functional studies of the found variant are needed to confirm that this is a causal mutation.
Taken together, the cause of ID was suspected in 44 (34.7%) patients (Figure 4) . Altogether, genetic causes were identified in and National Heart Lung and Blood Institute (NHLBI).
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